Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky, +17

Gut

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Wolfgang Hueber, Dhavalkumar D. Patel, Thaddeus P. Dryja, +5

Science Translational Medicine

Autoantigen microarrays for multiplex characterization of autoantibody responses

William H. Robinson, Carla DiGennaro, Wolfgang Hueber, +17

Nature Medicine

Autoantigen MicroarraysFunctional GenomicsEngineeringMedicineComputational Biology +5

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

Dominique Baeten, Xenofon Baraliakos, Jürgen Braun, +19

The Lancet

InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseMedicine +10

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

Iain B. McInnes, Joachim Sieper, Jürgen Braun, +12

Annals of the Rheumatic Diseases

Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice

Jonathan A. Hill, David Bell, William Brintnell, +7

The Journal of Experimental Medicine

Class IiDr4-ie Transgenic MiceImmunologyAntigen ProcessingImmunotherapy +16

Antigen microarray profiling of autoantibodies in rheumatoid arthritis

Wolfgang Hueber, Brian Kidd, Beren H. Tomooka, +10

Arthritis & Rheumatism

The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age‐dependent manner

Kevin D. Deane, Colin O’Donnell, Wolfgang Hueber, +8

Arthritis & Rheumatism

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Simon Bowman, Robert I. Fox, Thomas Dörner, +13

The Lancet

Rheumatoid DisorderRheumatologyAutoimmune DiseaseSjögren’s SyndromePhase 2B +10

Evidence that a neutrophil–keratinocyte crosstalk is an early target of <scp>IL</scp>‐17A inhibition in psoriasis

Kristian Reich, Kim Papp, Robert Matheson, +21

Experimental Dermatology

ImmunodeficienciesImmune RegulationImmunologyDermatologyImmune System +18